Palnox

Tablet / IV Injection

Composition : Palonosetron 0.5mg Tablet & .025mg IV Injection.

Indications : Moderately emetogenic cancer chemotherapy : prevention of acute and delayed nausea and vomiting associated with initial and repeat courses.

Highly emetogenic cancer chemotherapy : prevention of acute nausea and vomiting associated with initial and repeat courses.

Prevention of post operative nausea and vomiting for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

Dosage and administration : Chemotherapy-Induced Nausea and Vomiting (Dosage for Adults) Tablet : 0.5 mg tablet approximately 1 hour before the start of chemotherapy. **Injection :** A single 0.25mg I.V dose administered over 30 seconds. Dosing should occur 30 minutes before the start of chemotherapy.

Post operative Nausea and Vomiting (Dosage for Adults) : In case of 0.5 mg tablet, dose should be determined by the physician.

Or, as directed by the registered physicians.

Contraindication : Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Use in pregnancy and lactation : Pregnancy : Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Therefore, Palonosetron should be used during pregnancy only if clearly needed.

Nursing mothers : It is not known whether Palonosetron is excreted in human milk. So caution should be exercised when this tablet is administered to a nursing woman.

Side effects : Most commonly reported adverse effects are- headache, constipation, abdominal pain, fatigue, dizziness, insomnia.

Precaution : Hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other 5-HT_3 receptor antagonists.

Drug interactions : In vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.

Packing : Palnox 0.5 tablet : 2 x 14's tablets in blister pack.

Palnox 0.25 Injection (IV) : 1 x 3's Ampoules (5ml) in a blister pack.